Novo Nordisk A/S announced that it has received approval for its drug, Norditropin, from the FDA. Norditropin is for use on children with Turner's Sydrome.
Turner's Syndrome is a rare chromosomal condition that is caused by a complete or partial lack of the X chromosome in girls. Short stature is the most common feature of Turner's and Norditropin targets this. Results from a clinical trial found that 80% of patients receiving a higher than previously approved dosage reach normal adult height.
"Turner syndrome is a rare chromosomal disorder of females characterized
by short stature and the lack of sexual development at puberty. Among
affected females, physical features may include a short neck with a webbed
appearance, heart defects, kidney abnormalities and various other
malformations."
Comment Preview